State Street’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-951,675
| Closed | -$14.4M | – | 4956 |
|
|
2022
Q3 | $14.4M | Buy |
951,675
+7,675
| +0.8% | +$89.2K | ﹤0.01% | 2474 |
|
|
2022
Q2 | $7.08M | Sell |
944,000
-151,898
| -14% | -$1.07M | ﹤0.01% | 2917 |
|
|
2022
Q1 | $9.97M | Buy |
1,095,898
+13,885
| +1% | +$107K | ﹤0.01% | 2829 |
|
|
2021
Q4 | $7.6M | Buy |
1,082,013
+122,053
| +13% | +$1.28M | ﹤0.01% | 3050 |
|
|
2021
Q3 | $10.9M | Sell |
959,960
-32,047
| -3% | -$468K | ﹤0.01% | 2839 |
|
|
2021
Q2 | $15.9M | Buy |
992,007
+156,548
| +19% | +$2.69M | ﹤0.01% | 2633 |
|
|
2021
Q1 | $14.9M | Sell |
835,459
-140,434
| -14% | -$2.43M | ﹤0.01% | 2539 |
|
|
2020
Q4 | $13.2M | Sell |
975,893
-26,625
| -3% | -$322K | ﹤0.01% | 2478 |
|
|
2020
Q3 | $11.8M | Sell |
1,002,518
-123,738
| -11% | -$1.51M | ﹤0.01% | 2353 |
|
|
2020
Q2 | $16.6M | Sell |
1,126,256
-53,175
| -5% | -$787K | ﹤0.01% | 2138 |
|
|
2020
Q1 | $15.9M | Sell |
1,179,431
-32,552
| -3% | -$618K | ﹤0.01% | 1987 |
|
|
2019
Q4 | $29.3M | Buy |
1,211,983
+116,752
| +11% | +$2.42M | ﹤0.01% | 1879 |
|
|
2019
Q3 | $21.1M | Buy |
1,095,231
+118,596
| +12% | +$2.72M | ﹤0.01% | 2031 |
|
|
2019
Q2 | $28.9M | Buy |
976,635
+113,365
| +13% | +$4.37M | ﹤0.01% | 1860 |
|
|
2019
Q1 | $41M | Sell |
863,270
-30,344
| -3% | -$1.34M | ﹤0.01% | 1563 |
|
|
2018
Q4 | $32.3M | Buy |
893,614
+10,716
| +1% | +$503K | ﹤0.01% | 1641 |
|
|
2018
Q3 | $54.3M | Buy |
882,898
+129,807
| +17% | +$8.34M | ﹤0.01% | 1476 |
|
|
2018
Q2 | $50.9M | Sell |
753,091
-21,203
| -3% | -$1.19M | ﹤0.01% | 1480 |
|
|
2018
Q1 | $42M | Sell |
774,294
-28,714
| -4% | -$1.61M | ﹤0.01% | 1533 |
|
|
2017
Q4 | $48M | Buy |
803,008
+8,394
| +1% | +$509K | ﹤0.01% | 1451 |
|
|
2017
Q3 | $38.6M | Buy |
794,614
+93,089
| +13% | +$5.08M | ﹤0.01% | 1546 |
|
|
2017
Q2 | $36.9M | Sell |
701,525
-14,597
| -2% | -$680K | ﹤0.01% | 1551 |
|
|
2017
Q1 | $32.5M | Sell |
716,122
-104,522
| -13% | -$4.66M | ﹤0.01% | 1599 |
|
|
2016
Q4 | $31.1M | Buy |
820,644
+221,146
| +37% | +$8.36M | ﹤0.01% | 1573 |
|
|
2016
Q3 | $22.6M | Buy |
599,498
+5,520
| +0.9% | +$122K | ﹤0.01% | 1699 |
|
|
2016
Q2 | $10.5M | Sell |
593,978
-8,377
| -1% | -$136K | ﹤0.01% | 2200 |
|
|
2016
Q1 | $7.33M | Sell |
602,355
-5,252
| -0.9% | -$83.1K | ﹤0.01% | 2345 |
|
|
2015
Q4 | $14.8M | Buy |
607,607
+325,828
| +116% | +$7.6M | ﹤0.01% | 1939 |
|
|
2015
Q3 | $5M | Buy |
281,779
+68,927
| +32% | +$1.25M | ﹤0.01% | 2525 |
|
|
2015
Q2 | $3.76M | Sell |
212,852
-631,914
| -75% | -$11.6M | ﹤0.01% | 2779 |
|
|
2015
Q1 | $26.5M | Buy |
844,766
+715,534
| +554% | +$20.7M | ﹤0.01% | 1642 |
|
|
2014
Q4 | $3.77M | Buy |
129,232
+8,890
| +7% | +$225K | ﹤0.01% | 2717 |
|
|
2014
Q3 | $2.49M | Buy |
120,342
+11,631
| +11% | +$229K | ﹤0.01% | 2897 |
|
|
2014
Q2 | $2.69M | Buy |
108,711
+11,031
| +11% | +$191K | ﹤0.01% | 2919 |
|
|
2014
Q1 | $2.07M | Buy |
97,680
+31,624
| +48% | +$639K | ﹤0.01% | 3044 |
|
|
2013
Q4 | $1.19M | Buy |
+66,056
| New | +$860K | ﹤0.01% | 3219 |
|
State Street's AERI Position: Q4 2022 in Review
State Street sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 951,675 shares — an estimated $14.4M sold.
State Street first reported a position in AERI in Q4 2013 and held it in 36 quarters. The position peaked at $54.3M in Q3 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- State Street reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- State Street sold 951,675 Aerie Pharmaceuticals shares in Q4 2022, an estimated $14.4M.
- State Street first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 36 quarters.
- State Street's Aerie Pharmaceuticals position peaked at $54.3M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on State Street's 13F filing for Q4 2022, filed 14 Feb 2023.